Market cap
$224 Mln
Recently Viewed
Clear AllMarket cap
$224 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
11.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-89.4
Debt to Equity
0
Book Value
$--
EPS
$-1.8
Face value
--
Shares outstanding
14,788,400
CFO
$-561.40 Mln
EBITDA
$-481.95 Mln
Net Profit
$19.06 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Merrimack Pharmaceuticals (MACK)
| 12.8 | 2.7 | 2.9 | 21.0 | 33.5 | 28.3 | -6.9 |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Merrimack Pharmaceuticals (MACK)
| 17.0 | 193.1 | -43.3 | 118.7 | 16.7 | -62.1 | -54.6 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
President, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman
Mr. Gary L. Crocker M.B.A.
President, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman
Mr. Gary L. Crocker M.B.A.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Merrimack Pharmaceuticals Inc (MACK) is $15.13 (NASDAQ) as of 28-May-2024 09:30 EDT. Merrimack Pharmaceuticals Inc (MACK) has given a return of 33.49% in the last 3 years.
Since, TTM earnings of Merrimack Pharmaceuticals Inc (MACK) is negative, P/E ratio is not available.
The P/B ratio of Merrimack Pharmaceuticals Inc (MACK) is 11.38 times as on 28-May-2024, a 149 premium to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-158.97
|
10.01
|
|
2022
|
-103.91
|
8.34
|
|
2021
|
-20.70
|
3.58
|
|
2020
|
-29.58
|
5.60
|
|
2019
|
-1.93
|
2.37
|
The 52-week high and low of Merrimack Pharmaceuticals Inc (MACK) are Rs -- and Rs -- as of 25-Apr-2026.
Merrimack Pharmaceuticals Inc (MACK) has a market capitalisation of $ 224 Mln as on 28-May-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Merrimack Pharmaceuticals Inc (MACK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.